Danicopan

Phase 3

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

AZNPhase 3$273.6B

Danicopan Phase 3 Est. Readout

Danicopan• C3 Glomerulonephritis6

Q2 2027~QConfirmedSTALE

CT.gov

00%

Development History

Jul '26

AZNPhase 3$273.6B

✓Positive

Danicopan Phase 3 Results Expected

Danicopan• C3 Glomerulonephritis80

Jul 2026~Confirmed

CT.gov

Competitive Landscape

0 competitors in C3 Glomerulonephritis

View Full Landscape

Drug Information

Target Indication

C3 Glomerulonephritis

Clinical Trial

NCT03124368

Last updated: 4/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/19/2024

Voydeya

Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia

OrphanPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Saruparib (AZD5305)Phase 3

Ovarian Cancer

exenatide twice dailyPhase 3

Type 2 Diabetes Mellitus

AZD1152Phase 3

Acute Myeloid Leukemia

ChemotherapyPhase 3

Anticancer Treatment

Ciclesonide nasalPhase 3

Rhinitis, Allergic, Perennial

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts